Showing results (1-10 of 157) with videos related to
Sort By:
Pageof 16
Journal of Cardiovascular Pharmacology and Therapeutics|July 2, 2013
Lipid-lowering agentsMfon Ewang-Emukowhate, Anthony S WierzbickiClinical Medicine (London, England)|December 4, 2014
Dyslipidaemia: what's around the corner?Anthony S Wierzbicki, Dilinika Perera, Mfon Ewang-EmukowhateCurrent Pharmaceutical Design|June 24, 2014
Dyslipidaemia related to insulin resistance and cardiovascular disease in South Asian and West African populationsMfon Ewang-Emukowhate, Dilinika Perera, Anthony S D M WierzbickiScandinavian Journal of Clinical and Laboratory Investigation|December 19, 2023
Plasma or serum 5-hydroxyindoleacetic acid can be used interchangeably in patients with neuroendocrine tumoursMfon Ewang-Emukowhate, Krithika Subramaniam, Francis Lam, et al.Current Opinion in Lipidology|July 14, 2010
Fibrates: no ACCORD on their use in the treatment of dyslipidaemiaAnthony S WierzbickiDiabetes & Vascular Disease Research|July 27, 2007
Homocysteine and cardiovascular disease: a review of the evidenceAnthony S WierzbickiExpert Opinion on Investigational Drugs|October 27, 2004
Lipid-lowering therapies in developmentAnthony S WierzbickiCurrent Opinion in Cardiology|May 9, 2009
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemiaAnthony S WierzbickiExpert Review of Neurotherapeutics|October 9, 2009
Stroke in systemic lupus erythematosusAnthony S WierzbickiCurrent Opinion in Lipidology|August 15, 2017
The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of careAnthony S WierzbickiPageof 16